$2.31 Billion is the total value of Vivo Capital, LLC's 59 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | Instil Bio Inc | $241,245,000 | -23.0% | 12,486,787 | 0.0% | 10.44% | -5.1% | |
| ALXO | ALX Oncology Holdings Inc | $230,752,000 | -25.8% | 4,220,048 | 0.0% | 9.99% | -8.7% | |
| NFH | New Frontier Health Corp | $159,731,000 | -1.2% | 14,300,000 | 0.0% | 6.92% | +21.8% | |
| HRMY | Harmony Biosciences Holdings Inc | $128,004,000 | -14.6% | 4,534,341 | 0.0% | 5.54% | +5.2% | |
| GTH | Genetron Holdings Ltdads | $127,685,000 | -6.2% | 6,339,860 | 0.0% | 5.53% | +15.6% | |
| ALGS | Aligos Therapeutics Inc | $72,306,000 | -10.4% | 3,547,030 | 0.0% | 3.13% | +10.4% | |
| BOLT | Bolt Therapeutics Inc | $59,850,000 | -53.0% | 3,871,291 | 0.0% | 2.59% | -42.1% | |
| KALV | KalVista Pharmaceuticals Inc. | $44,645,000 | -6.7% | 1,863,296 | 0.0% | 1.93% | +14.9% | |
| SVA | Sinovac Biotech Ltd. | $38,173,000 | 0.0% | 5,900,000 | 0.0% | 1.65% | +23.1% | |
| ISEE | Iveric Bio Inc | $37,649,000 | +2.1% | 5,966,527 | 0.0% | 1.63% | +25.8% | |
| SRRA | Sierra Oncology, Inc | $37,325,000 | +13.0% | 1,917,074 | 0.0% | 1.62% | +39.2% | |
| OLMA | Olema Pharmaceuticals Inc | $34,655,000 | -15.7% | 1,238,575 | 0.0% | 1.50% | +3.9% | |
| TERN | Terns Pharmaceuticals Inc | $32,797,000 | -44.3% | 2,675,133 | 0.0% | 1.42% | -31.3% | |
| ZLAB | Zai Lab Ltd ADRadr | $30,973,000 | +32.6% | 175,000 | 0.0% | 1.34% | +63.3% | |
| KDMN | Kadmon Holdings Inc | $22,514,000 | -0.5% | 5,817,459 | 0.0% | 0.98% | +22.6% | |
| VRNA | Verona Pharma PLC ADRads | $19,937,000 | -21.8% | 3,048,507 | 0.0% | 0.86% | -3.7% | |
| AVDL | Avadel Pharmaceuticals PLCadr | $19,767,000 | -25.6% | 2,937,093 | 0.0% | 0.86% | -8.3% | |
| NKTX | Nkarta Inc | $16,232,000 | -3.7% | 512,225 | 0.0% | 0.70% | +18.8% | |
| EIGR | Eiger BioPharmaceuticals Inc | $15,262,000 | -3.7% | 1,791,257 | 0.0% | 0.66% | +18.7% | |
| CYTK | Cytokinetics Inc | $13,853,000 | -14.9% | 700,000 | 0.0% | 0.60% | +4.9% | |
| MREO | Mereo Biopharma Group PLCads | $13,380,000 | -5.9% | 4,220,938 | 0.0% | 0.58% | +15.8% | |
| CRIS | Curis Inc | $12,537,000 | -28.7% | 1,553,500 | 0.0% | 0.54% | -12.1% | |
| DYN | Dyne Therapeutics Inc | $12,154,000 | +35.5% | 577,642 | 0.0% | 0.53% | +67.0% | |
| ARWR | Arrowhead Pharmaceuticals Inc | $11,380,000 | +24.9% | 137,411 | 0.0% | 0.49% | +54.1% | |
| KURA | Kura Oncology Inc | $10,952,000 | -26.2% | 525,262 | 0.0% | 0.47% | -9.2% | |
| DSGN | Design Therapeutics | $10,561,000 | -33.5% | 530,991 | 0.0% | 0.46% | -18.1% | |
| ZYME | Zymeworks Inc | $9,924,000 | +9.9% | 286,064 | 0.0% | 0.43% | +35.2% | |
| ASLN | Aslan Pharmaceuticals Ltdads | $9,375,000 | -1.5% | 2,840,909 | 0.0% | 0.41% | +21.6% | |
| CDXS | Codexis, Inc | $8,795,000 | -1.0% | 388,144 | 0.0% | 0.38% | +22.1% | |
| STSA | Satsuma Pharmaceuticals Inc | $8,688,000 | +19.3% | 1,232,394 | 0.0% | 0.38% | +46.9% | |
| LRMR | Larimar Therapeutics Inc | $7,853,000 | -32.8% | 799,662 | 0.0% | 0.34% | -17.3% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $6,489,000 | -0.2% | 500,732 | 0.0% | 0.28% | +22.7% | |
| FIXX | Homology Medicines, Inc. | $6,202,000 | -22.7% | 853,143 | 0.0% | 0.27% | -5.0% | |
| ORTX | Orchard Therapeutics plcads | $5,820,000 | -39.5% | 1,325,736 | 0.0% | 0.25% | -25.4% | |
| IMVT | Immunovant Inc | $5,632,000 | -34.1% | 532,847 | 0.0% | 0.24% | -18.7% | |
| SNDX | Syndax Pharmaceuticals Inc | $5,494,000 | -23.2% | 320,000 | 0.0% | 0.24% | -5.2% | |
| TXG | 10X Genomics Inc | $2,898,000 | +8.2% | 14,798 | 0.0% | 0.12% | +33.0% | |
| ZGNX | Zogenix Inc | $1,814,000 | -11.5% | 105,000 | 0.0% | 0.08% | +9.7% | |
| DTIL | Precision Biosciences Inc | $1,756,000 | +20.9% | 140,255 | 0.0% | 0.08% | +49.0% | |
| TCDA | Tricida, Inc. | $755,000 | -18.3% | 174,763 | 0.0% | 0.03% | +3.1% | |
| MTCR | Metacrine Inc | $556,000 | -38.8% | 146,426 | 0.0% | 0.02% | -25.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.